Suppression of Primary Aldosteronism and Resistant Hypertension by the Peroxisome Proliferator-activated Receptor Gamma Agonist Pioglitazone

• Published in: The American journal of the medical sciences 2013-06, Vol.345 (6), p.497-500
• Main Authors: Kashiwagi, Yusuke, MD, Mizuno, Yuji, MD, PhD, Harada, Eisaku, MD, PhD, Shono, Makoto, MD, PhD, Morita, Sumio, MD, Yasue, Hirofumi, MD, PhD, Yoshimura, Michihiro, MD, PhD, Yano, Mayumi, MD, PhD
• Format: Article
• Language: English
• Subjects: Aldosterone; Aldosterone - blood; Blood Pressure - drug effects; Blood Pressure - physiology; Comorbidity; Humans; Hyperaldosteronism - blood; Hyperaldosteronism - drug therapy; Hyperaldosteronism - epidemiology; Hypertension - drug therapy; Hypertension - epidemiology; Hypertension - physiopathology; Internal Medicine; Male; Middle Aged; Peroxisome proliferator-activated receptor γ; Pioglitazone; PPAR gamma - agonists; Primary aldosteronism; Resistant hypertension; Thiazolidinediones - pharmacology; Thiazolidinediones - therapeutic use; Treatment Outcome
• ISSN: 0002-9629; 1538-2990
• DOI: 10.1097/MAJ.0b013e31827ad893

Abstract The peroxisome proliferator-activated receptor gamma (PPAR γ) agonists have been reported to have antiproliferative and tumor-suppressive effects. We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR γ agonist pioglitazone. He had drug-resistant hypertension, hypokalemia, and diabetes mellitus. The diagnosis of PA was confirmed by the oral sodium loading test (20.5 μg/d of urinary aldosterone) and Captopril challenge test (19.5 ng/dL of plasma aldosterone). Computed tomography imaging revealed no apparent adrenal mass. The result of the posture stimulation test was consistent with the diagnosis of idiopathic adrenal hyperplasia. On administration of pioglitazone (30 mg/d) and nifedipine (40 mg/d), hypertension and hypokalemia improved and plasma aldosterone decreased for more than 6 months. The sodium loading test done after 6 months of the administration revealed the near normal results (11.2 ng/dL of plasma aldosterone and 13.1 μg/d of urinary aldosterone). The findings indicated that pioglitazone suppressed PA.